SB 239063, , >98% (HPLC)

Code: S0569-5MG D2-231

Application

SB 239063 has been used to determine the roles of c-Jun N-terminal kinase (JNK), p38 MAP kinase, and extracellular signal regulated protein kinase (ERK)/p42/p44 m...


read more

Your Price
€215.32 5MG
€264.84 inc. VAT

Application

SB 239063 has been used to determine the roles of c-Jun N-terminal kinase (JNK), p38 MAP kinase, and extracellular signal regulated protein kinase (ERK)/p42/p44 mitogen activated protein kinase (MAPK) on the viability and apoptosis of cardiomyocytes under glutathione S-transferase (GST) inhibition. It has also been used in neuron-microglia conditioned media (CM) experiments and pharmacokinetics.

Biochem/physiol Actions

Potent p38 MAP kinase inhibitor. Selective for α and β. No activity against γ and δ isoforms.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

SB 239063 helps to decrease neutrophilia, inflammatory cytokines, matrix metallopeptidase 9 (MMP-9) and fibrosis in the lung.

Legal Information

Sold for research purposes under agreement from GlaxoSmithKline

Packaging

5, 25 mg in glass bottle

assay>98% (HPLC)
colorwhite
formpowder
InChI keyZQUSFAUAYSEREK-WKILWMFISA-N
InChI1S/C20H21FN4O2/c1-27-20-22-11-10-17(24-20)19-18(13-2-4-14(21)5-3-13)23-12-25(19)15-6-8-16(26)9-7-15/h2-5,10-12,15-16,26H,6-9H2,1H3/t15-,16-
mp206-207.2 °C
originatorGlaxoSmithKline
Quality Level100
SMILES stringCOc1nccc(n1)-c2c(ncn2[C@@H]3CC[C@@H](O)CC3)-c4ccc(F)cc4
solubilityDMSO: 11 mg/mL, H2O: insoluble
storage temp.2-8°C
Cas Number193551-21-2
This product has met the following criteria to qualify for the following awards:



PROCEED TO CHECKOUT

HAVE AN ACCOUNT? LOGIN


GUEST CHECKOUT

Proceed as a guest. You will have the option to register to access exclusive pricing and stock availability features after checkout.